Search Results
Oct 29, 2025, 05:49 ET Thousand Oaks Biologics Showcases Integrated ADC CRDMO Solutions & Media Innovation for Industrialization at CPHI Frankfurt 2025
design and optimization, antibody discovery and engineering, linker-payload screening and conjugation, developability assessment, pharmacology and PK/PD studies, and early-stage sample preparation. This integrated approach, extending to structural characterization and novel formulation development, creates
More news about: Thousand Oaks Biologics
Oct 28, 2025, 17:16 ET The Inner Circle acknowledges, Cha-Mei Tang as a Pinnacle Professional Member Inner Circle of Excellence
(3) provide companion diagnostics - not requiring tissue, (4) monitor biomarker expression or change of biomarker – example: change of PD-L1 expression on the tumor. PD-L1 expression predicts treatment response of immunotherapy, (5) detect cancer recurrence and minimal residual disease (MRD), and (6) deliver
More news about: The Inner Circle
Oct 28, 2025, 16:35 ET FIRST RESPONDERS CHILDREN'S FOUNDATION HONORS FIRST RESPONDER HEROES AT SIXTH ANNUAL NATIONAL FIRST RESPONDERS DAY CELEBRATION
Schneider, New York City Fire DepartmentNYPD Community Hero Award: Officer Rich Wong, New York City Police DepartmentMTA PD Community Hero Award: Officers Scott Gulick & Christopher Capozzoli, Metropolitan Transportation Authority Police Department
More news about: First Responders Children's Foundation
Oct 28, 2025, 08:11 ET Fosun Pharma Announces 2025Q3 Financial Results
pipelines, including HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) and HLX43 (PD-L1-targeted antibody-drug conjugate). Fosun Pharma's self-developed innovative anti-PD-1 monoclonal antibody (mAb) Han Si Zhuang (serplulimab injection) is making steady progress across
More news about: Fosun Pharma
Oct 28, 2025, 07:30 ET Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers
More news about: Oncolytics Biotech® Inc.
Oct 27, 2025, 08:30 ET Advancing Cell Therapy Development with Integrated Analytical and Process Strategies, Upcoming Webinar Hosted by Xtalks
how analytical and process development (PD/AD) workflows can rapidly generate "fit-for-purpose " testing to support small-scale PD work on accelerated timelines. The featured speakers will discuss how emerging technologies are being applied in cell therapy PD/AD.
More news about: Xtalks
Oct 27, 2025, 08:30 ET Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
presented detailed results from its global phase 3 trial of Cylembio(R) (imsapepimut and etimupepimut, adjuvanted), in combination with Merck's anti-PD-1 therapy KEYTRUDA(R) (pembrolizumab), for the first-line treatment of patients with unresectable or metastatic (advanced) melanoma. The data, presented
More news about: NetworkNewsWire
Oct 27, 2025, 08:19 ET Betterview Property Intelligence by Nearmap Now Integrated with Guidewire PolicyCenter
www.nearmap.com/partners/guidewire or meet Nearmap at Guidewire Connections in Las Vegas from October 27-30th at booth PD-G+1 About Nearmap Nearmap is the location intelligence provider customers rely on for consistent, reliable,
More news about: Nearmap
Oct 27, 2025, 07:00 ET China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)
gotistobart as monotherapy compared to the standard-of-care chemotherapy (docetaxel) in patients with metastatic sqNSCLC that progressed under previous PD-(L)1-inhibitor treatment. The initiation of the Phase 3 trial was based on positive safety and efficacy data from an ongoing Phase 1/2 trial (NCT04140526) with
More news about: OncoC4
Oct 27, 2025, 07:00 ET Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development
More news about: Compugen Ltd.
Oct 27, 2025, 07:00 ET Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents
More news about: Actinium Pharmaceuticals, Inc.
Oct 27, 2025, 06:50 ET La nueva cara de la aventura: la RAV4 2026 llega este invierno
características: Sistema de precolisión con detección de peatones (PCS con PD): está diseñado para ayudar a detectar un vehículo, peatón, ciclista o motociclista y proporcionar una advertencia de colisión frontal sonora o visual
More news about: Toyota Motor North America
Oct 26, 2025, 22:30 ET Baseus Launches Nomos NU1 Air Spacemate 12-in-1 (MAC) Docking Station to Improve Productivity Across Multiple Displays
pixels at 60 Hz), 2 USB-C data ports (10 Gbps), 2 USB-A data ports (5 Gbps), and 2 USB-A ports (480 Mbps) for legacy devices. It features a 100W USB-C PD port, and a 1Gb Ethernet port, supporting a wide range of devices and professional workflows. Enjoy seamless connectivity with a single USB-C connection,
More news about: BASEUS TECHNOLOGY (HK) CO, LIMITED
Oct 26, 2025, 22:30 ET Baseus bringt die Nomos NU1 Air Spacemate 12-in-1 (MAC) Dockingstation auf den Markt, um die Produktivität bei der Verwendung mehrerer Bildschirme zu steigern
2 USB-C-Datenanschlüsse (10 Gbit/s), 2 USB-A-Datenanschlüsse (5 Gbit/s) und 2 USB-A-Anschlüsse (480 Mbit/s) für ältere Geräte. Es verfügt über einen 100-W-USB-C-PD-Anschluss und einen 1-Gb-Ethernet-Anschluss und unterstützt eine Vielzahl von Geräten und professionellen Workflows. Genießen Sie nahtlose Konnektivität
More news about: BASEUS TECHNOLOGY (HK) CO, LIMITED
Oct 26, 2025, 21:00 ET Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
cells and NALM6 leukemia cells with serial antigen restimulation on Days 7 and 14, ATG-201 induced significantly lower expression of exhaustion markers PD-1 and Tim-3 as measured by flow cytometry. This reduced T-cell exhaustion underscores the advantages of the AnTenGager™ structure and novel CD3 binder,
More news about: Antengene Corporation Limited
Oct 24, 2025, 08:30 ET Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents
More news about: Actinium Pharmaceuticals, Inc.
Oct 23, 2025, 19:30 ET HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
encouraged by the excellent safety profile and initial responses observed in heavily pretreated patients. These monotherapy data establish safety, PK/PD, and early activity, providing the foundation for our ongoing combination trials testing HCB101 layered onto standard backbones in multiple tumor types.
More news about: HanchorBio Inc.
Oct 23, 2025, 17:31 ET Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight
Sciences' Zimberelimab, a PD-1 inhibitor, and domvanalimab, a TIGIT inhibitor, are being developed by Arcus Biosciences in partnership with Gilead and are under investigation as a combined dual checkpoint blockade therapy. Zimberelimab works by reactivating T-cells through PD-1 inhibition, while domvanalimab
More news about: DelveInsight Business Research, LLP
Oct 23, 2025, 09:21 ET METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
system disorders such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury (TBI), or Parkinson's disease (PD). The condition can severely impair social functioning and quality of life, while exacerbating the burden of underlying neurological diseases.
More news about: METiS TechBio
Oct 23, 2025, 09:03 ET MasterClass Launches Certificate Course with X, The Moonshot Factory: Breakthrough Innovation Strategy
https://youtu.be/63eK7DcR0m4?si=mzDe_Ag_p4Ybq3Pd Download images here:
More news about: MasterClass
Oct 23, 2025, 07:00 ET HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs
More news about: HanchorBio Inc.
Oct 22, 2025, 20:00 ET Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
Positive efficacy and safety data have been observed in the monotherapy trial targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, CRC, NEN and HCC. Final data from the study of HBM4003 in combination with toripalimab for advanced HCC were published in
More news about: Harbour BioMed
Oct 22, 2025, 12:00 ET GIGABYTE annonce la disponibilité des ordinateurs portables GAMING A16 PRO et GAMING A18
productivité qui accordent une grande importance à l'espace disponible sur l'écran. Avec la prise en charge de la charge rapide Type-C PD 3.0 et la batterie avec une durée de vie d'une journée, le GAMING A16 PRO et le GAMING A18 sont conçus pour équilibrer la performance, l'endurance et
More news about: GIGABYTE
Oct 22, 2025, 10:00 ET The Next Adventure Begins: 2026 RAV4 Arrives this Winter
features: Pre-Collision System with Pedestrian Detection (PCS w/PD) is designed to help detect a vehicle, pedestrian, bicyclist or motorcyclist and provide an audio/visual forward-collision warning under certain circumstances.
More news about: Toyota Motor North America
Oct 22, 2025, 08:30 ET OncoHost Receives New York State Laboratory Permit, Expanding Availability of PROphetNSCLC® Precision Oncology Test
(mNSCLC). Using a single blood sample, the test analyzes thousands of plasma proteins to generate a personalized probability of clinical benefit from PD-1/PD-L1 inhibitors - empowering physicians to optimize treatment selection and improve patient outcomes. "This permit is a significant
More news about: OncoHost